Conference
Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up
Abstract
Abstract
Authors
Leber B; Cervantes F; Spector N; Lipton JH; Etienne G; Pasquini R; Clementino NC; Guerci-Bresler A; Forrest D; Schwarer AP
Volume
122
Pagination
pp. 94-95
Publisher
American Society of Hematology
Publication Date
November 15, 2013
DOI
10.1182/blood.v122.21.94.94
Conference proceedings
Blood
Issue
21
ISSN
0006-4971